Refine by
Medical Industry News: This-Week
2 news found
Confo Therapeutics today reported preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), with findings presented at ENDO 2026. The data support CFTX-2034 as a potential first-in-class PBH therapy and advance the program toward IND-enabling studies.CFTX-2034 is a long-acting, highly selective agonistic antibody designed to target ...
Confo Therapeutics today reported preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), with findings presented at ENDO 2026. The data support CFTX-2034 as a potential first-in-class PBH therapy and advance the program toward IND-enabling studies.CFTX-2034 is a long-acting, highly selective agonistic antibody designed to target ...